Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

This publication has 111 references indexed in Scilit:

• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR * Trial)
  Published by Elsevier ,2003
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.
  The American Journal of Cardiology, 1998
• What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?
  Atherosclerosis, 1997
• Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia
  The American Journal of Cardiology, 1995
• Dietary phytosterols: A review of metabolism, benefits and side effects
  Life Sciences, 1995
• Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications
  The American Journal of Cardiology, 1993
• Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics
  Published by Elsevier ,1993
• Comparison of the efficacy of Questran light, a new formulation of cholestyramine powder, to regular Questran in maintaining lowered plasma cholesterol levels
  The American Journal of Cardiology, 1991
• Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia
  New England Journal of Medicine, 1990